OVID News and Press, Ovid Therapeutics Inc. From 11/08/22

Ovid intends to initiate a Phase 1 study in healthy volunteers in Q4 2022, following the FDA clearance of an Investigational New Drug (IND) application for OV329, its GABA-aminotransferase inhibitor The Company ended Q3 2022 with cash, cash equivalents and marketable securities of $...

NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will present at the L...

NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will present at the H...

The following slide deck was published by Ovid Therapeutics Inc. in conjunction with this event. For further details see: Ovid Therapeutics (OVID) Corporate Presentation - Slideshow

Ovid Therapeutics press release ( NASDAQ: OVID ): Q2 GAAP EPS of -$0.21 beats by $0.04 . Cash, cash equivalents and marketable securities as of June 30, 2022 was $152.4 million For further details see: Ovid Therapeutics GAAP EPS of -$0.21 beats by $0.04 ...

Anticipates filing an Investigational New Drug application for OV329, a potent GABA-aminotransferase inhibitor, and initiating a Phase 1 trial in the second half of 2022 Presented preclinical data from six animal models reinforcing the seizure-reducing potential of OV329 at two le...

Gainers: Cowen ( COWN ) +16% . CommScope Holding Company ( COMM ) +5% . Red Robin Gourmet Burgers ( RRGB ) +3% . The RealReal ( REAL ) +2% . AbCellera Biologics ( ABCL ) +2% . Losers: Nyxoah ( NYXH ) -7% . Ovi...

OV329 demonstrated robust anti-seizure activity in multiple preclinical seizure and epilepsy models, including treatment-resistant seizures Data demonstrate OV329 has the potential for an improved ocular safety profile and therapeutic index compared to other GABA-aminotransferase ...

Ovid Therapeutics press release (NASDAQ:OVID): Q1 GAAP EPS of -$0.23 misses by $0.02. Revenue of $1.45M (-99.3% Y/Y). For further details see: Ovid Therapeutics GAAP EPS of -$0.23 misses by $0.02, revenue of $1.45M

Ovid anticipates filing an investigational new drug application (IND) for OV329, a potent GABA aminotransferase inhibitor, and initiating Phase 1 trials in the fourth quarter of 2022 Data supporting OV329 in rare and treatment-resistant epilepsies expected to be presented at the upcom...